Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorVinaiphat, Aradaen_US
dc.contributor.authorLow, Jee Keemen_US
dc.contributor.authorYeoh, Kheng Weien_US
dc.contributor.authorChng, Wee Jooen_US
dc.contributor.authorSze, Siu Kwanen_US
dc.identifier.citationVinaiphat, A., Low, J. K., Yeoh, K. W., Chng, W. J. & Sze, S. K. (2021). Application of advanced mass spectrometry-based proteomics to study hypoxia driven cancer progression. Frontiers in Oncology, 11, 559822-.
dc.description.abstractCancer is one of the largest contributors to the burden of chronic disease in the world and is the second leading cause of death globally. It is associated with episodes of low-oxygen stress (hypoxia or ischemia/reperfusion) that promotes cancer progression and therapeutic resistance. Efforts have been made in the past using traditional proteomic approaches to decipher oxygen deprivation stress-related mechanisms of the disease initiation and progression and to identify key proteins as a therapeutic target for the treatment and prevention. Despite the potential benefits of proteomic in translational research for the discovery of new drugs, the therapeutic outcome with this approach has not met expectations in clinical trials. This is mainly due to the disease complexity which possess a multifaceted molecular pathology. Therefore, novel strategies to identify and characterize clinically important sets of modulators and molecular events for multi-target drug discovery are needed. Here, we review important past and current studies on proteomics in cancer with an emphasis on recent pioneered labeling approaches in mass spectrometry (MS)-based systematic quantitative analysis to improve clinical success. We also discuss the results of the selected innovative publications that integrate advanced proteomic technologies (e.g. MALDI-MSI, pSILAC/SILAC/iTRAQ/TMT-LC-MS/MS, MRM-MS) for comprehensive analysis of proteome dynamics in different biosystems, including cell type, cell species, and subcellular proteome (i.e. secretome and chromatome). Finally, we discuss the future direction and challenges in the application of these technological advancements in mass spectrometry within the context of cancer and hypoxia.en_US
dc.description.sponsorshipMinistry of Education (MOE)en_US
dc.description.sponsorshipNational Medical Research Council (NMRC)en_US
dc.relation.ispartofFrontiers in Oncologyen_US
dc.rights© 2021 Vinaiphat, Low, Yeoh, Chng and Sze. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.en_US
dc.titleApplication of advanced mass spectrometry-based proteomics to study hypoxia driven cancer progressionen_US
dc.typeJournal Articleen
dc.contributor.schoolSchool of Biological Sciencesen_US
dc.description.versionPublished versionen_US
dc.description.acknowledgementThis work is in part supported by the Singapore Ministry of Education (MOE2016-T2-2-018 and MOE2018-T1-001-078), and Singapore National Medical Research Council (NMRC/OFIRG/0003/2016).en_US
item.fulltextWith Fulltext-
Appears in Collections:SBS Journal Articles
Files in This Item:
File Description SizeFormat 
fonc-11-559822.pdf1.67 MBAdobe PDFThumbnail

Citations 20

Updated on Jun 16, 2024

Web of ScienceTM
Citations 20

Updated on Oct 26, 2023

Page view(s)

Updated on Jun 17, 2024

Download(s) 50

Updated on Jun 17, 2024

Google ScholarTM




Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.